David Ryall Brown

Healx Ltd. engages in the development of a platform that enables treatment predictions for rare diseases. It offers HealNet, an artificial intelligence platform for rare diseases. Its solutions include orphan disease strategy, indication expansion, combination therapies, and shelved assets. The company was founded by Tim Guilliams and David Ryall Brownn and is headquartered in Cambridge, the United Kingdom.

Healx Ltd. engages in the development of a platform that enables treatment predictions for rare diseases. It offers HealNet, an artificial intelligence platform for rare diseases. Its solutions include orphan disease strategy, indication expansion, combination therapies, and shelved assets. The company was founded by Tim Guilliams and David Ryall Brownn and is headquartered in Cambridge, the United Kingdom.

Healx Ltd. engages in the development of a platform that enables treatment predictions for rare diseases. It offers HealNet, an artificial intelligence platform for rare diseases. Its solutions include orphan disease strategy, indication expansion, combination therapies, and shelved assets. The company was founded by Tim Guilliams and David Ryall Brownn and is headquartered in Cambridge, the United Kingdom.

Healx Ltd. engages in the development of a platform that enables treatment predictions for rare diseases. It offers HealNet, an artificial intelligence platform for rare diseases. Its solutions include orphan disease strategy, indication expansion, combination therapies, and shelved assets. The company was founded by Tim Guilliams and David Ryall Brownn and is headquartered in Cambridge, the United Kingdom.

Healx Ltd. engages in the development of a platform that enables treatment predictions for rare diseases. It offers HealNet, an artificial intelligence platform for rare diseases. Its solutions include orphan disease strategy, indication expansion, combination therapies, and shelved assets. The company was founded by Tim Guilliams and David Ryall Brownn and is headquartered in Cambridge, the United Kingdom.

ProFactor Pharma Ltd. develops and supplies recombinant blood factors for the treatment of haemophilia. The firm commercialise and supply recombinant blood factors for the treatment of haemophilia to a undersupplied world market, starting with recombinant human Factor VIII (rhFVIII). The company was founded by Richard John Cruse, Ian Garner, Bruce Vernon, Hugh Ilyine and John H. McVey in 2009 and is headquartered in Midlothian, the United Kingdom.